| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 65 | 2022 | 136 | 8.620 |
Why?
|
| Echocardiography | 55 | 2021 | 176 | 4.580 |
Why?
|
| Carotid Arteries | 17 | 2022 | 53 | 3.890 |
Why?
|
| Neovascularization, Pathologic | 13 | 2021 | 64 | 3.020 |
Why?
|
| Ultrasonography | 29 | 2022 | 271 | 3.000 |
Why?
|
| Carotid Stenosis | 11 | 2022 | 21 | 2.640 |
Why?
|
| Vasa Vasorum | 9 | 2014 | 9 | 2.380 |
Why?
|
| Atherosclerosis | 9 | 2020 | 76 | 2.220 |
Why?
|
| Heart Diseases | 6 | 2021 | 75 | 2.220 |
Why?
|
| Plaque, Atherosclerotic | 9 | 2022 | 23 | 2.140 |
Why?
|
| Tunica Intima | 12 | 2011 | 27 | 2.050 |
Why?
|
| Carotid Artery Diseases | 11 | 2019 | 41 | 1.920 |
Why?
|
| Tunica Media | 10 | 2011 | 15 | 1.920 |
Why?
|
| Image Enhancement | 11 | 2018 | 60 | 1.840 |
Why?
|
| Microbubbles | 8 | 2020 | 9 | 1.790 |
Why?
|
| Albumins | 16 | 2013 | 37 | 1.610 |
Why?
|
| Cardiovascular Diseases | 9 | 2020 | 428 | 1.220 |
Why?
|
| Arteriosclerosis | 5 | 2010 | 16 | 1.100 |
Why?
|
| Gene Transfer Techniques | 3 | 2016 | 36 | 1.100 |
Why?
|
| Drug Delivery Systems | 4 | 2016 | 39 | 1.040 |
Why?
|
| Humans | 100 | 2022 | 30997 | 1.020 |
Why?
|
| Diagnostic Imaging | 5 | 2019 | 90 | 1.020 |
Why?
|
| Coronary Vessels | 12 | 2019 | 46 | 0.970 |
Why?
|
| Coronary Disease | 10 | 2017 | 82 | 0.920 |
Why?
|
| Ultrasonography, Interventional | 4 | 2013 | 70 | 0.910 |
Why?
|
| Fluorocarbons | 6 | 2019 | 17 | 0.860 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2018 | 47 | 0.860 |
Why?
|
| Ultrasonics | 7 | 2016 | 17 | 0.850 |
Why?
|
| Genetic Therapy | 5 | 2019 | 93 | 0.840 |
Why?
|
| Coronary Artery Disease | 6 | 2019 | 138 | 0.810 |
Why?
|
| Carotid Intima-Media Thickness | 4 | 2016 | 24 | 0.730 |
Why?
|
| Injections, Intravenous | 10 | 2015 | 56 | 0.710 |
Why?
|
| Forecasting | 3 | 2021 | 114 | 0.690 |
Why?
|
| Coronary Circulation | 17 | 2004 | 43 | 0.680 |
Why?
|
| Connective Tissue | 2 | 2010 | 26 | 0.670 |
Why?
|
| Coronary Thrombosis | 1 | 2019 | 5 | 0.660 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 121 | 0.650 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2019 | 17 | 0.650 |
Why?
|
| Thrombosis | 2 | 2018 | 63 | 0.650 |
Why?
|
| Animals | 32 | 2020 | 4723 | 0.640 |
Why?
|
| Male | 45 | 2021 | 16445 | 0.630 |
Why?
|
| Apolipoprotein A-I | 3 | 2019 | 5 | 0.630 |
Why?
|
| Atrial Appendage | 1 | 2018 | 57 | 0.600 |
Why?
|
| Heart Ventricles | 10 | 2019 | 173 | 0.600 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 81 | 0.580 |
Why?
|
| Plasmids | 2 | 2015 | 45 | 0.580 |
Why?
|
| Microspheres | 11 | 2016 | 40 | 0.560 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2010 | 4 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2009 | 213 | 0.540 |
Why?
|
| Middle Aged | 36 | 2021 | 10195 | 0.540 |
Why?
|
| Female | 39 | 2021 | 16983 | 0.510 |
Why?
|
| Aged | 32 | 2021 | 10048 | 0.500 |
Why?
|
| Lipoproteins, HDL | 4 | 2019 | 30 | 0.460 |
Why?
|
| Hypoalphalipoproteinemias | 1 | 2014 | 1 | 0.460 |
Why?
|
| Primary Prevention | 1 | 2014 | 41 | 0.460 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2013 | 1 | 0.450 |
Why?
|
| Endosonography | 1 | 2013 | 11 | 0.440 |
Why?
|
| Endothelium, Vascular | 2 | 2011 | 65 | 0.430 |
Why?
|
| Hypoxia | 2 | 2016 | 63 | 0.430 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 31 | 0.430 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2022 | 8 | 0.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 66 | 0.400 |
Why?
|
| Risk Factors | 11 | 2020 | 2588 | 0.390 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 818 | 0.380 |
Why?
|
| Myocardial Infarction | 5 | 2019 | 173 | 0.370 |
Why?
|
| Vascular Diseases | 1 | 2010 | 52 | 0.340 |
Why?
|
| Adult | 18 | 2021 | 8931 | 0.330 |
Why?
|
| Ventricular Function, Left | 2 | 2003 | 54 | 0.320 |
Why?
|
| Biomarkers | 8 | 2015 | 733 | 0.320 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 782 | 0.300 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2019 | 13 | 0.300 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 17 | 0.300 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 12 | 0.300 |
Why?
|
| Cholesterol, HDL | 3 | 2015 | 30 | 0.300 |
Why?
|
| Myocardial Reperfusion | 2 | 1998 | 7 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 344 | 0.280 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 583 | 0.270 |
Why?
|
| Ultrasonography, Doppler | 3 | 2013 | 15 | 0.270 |
Why?
|
| Brachial Artery | 3 | 2015 | 8 | 0.250 |
Why?
|
| Child | 3 | 2021 | 1430 | 0.250 |
Why?
|
| Retrospective Studies | 9 | 2018 | 3658 | 0.250 |
Why?
|
| Stroke Volume | 2 | 2003 | 70 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 817 | 0.250 |
Why?
|
| Predictive Value of Tests | 6 | 2013 | 549 | 0.240 |
Why?
|
| Vasodilation | 4 | 2020 | 19 | 0.240 |
Why?
|
| Time Factors | 7 | 2015 | 1672 | 0.240 |
Why?
|
| Blood Vessels | 1 | 2004 | 18 | 0.240 |
Why?
|
| Diffusion of Innovation | 1 | 2004 | 40 | 0.230 |
Why?
|
| Carotid Artery, Common | 1 | 2004 | 8 | 0.230 |
Why?
|
| Risk Assessment | 6 | 2021 | 718 | 0.230 |
Why?
|
| Radionuclide Angiography | 1 | 2003 | 2 | 0.230 |
Why?
|
| Inflammation | 3 | 2011 | 362 | 0.220 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 68 | 0.220 |
Why?
|
| Heart Atria | 2 | 2002 | 68 | 0.210 |
Why?
|
| Adolescent | 4 | 2021 | 2401 | 0.210 |
Why?
|
| Heart Arrest, Induced | 4 | 1995 | 4 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 150 | 0.210 |
Why?
|
| Coronary Angiography | 6 | 2019 | 95 | 0.210 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 20 | 0.200 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2002 | 5 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2013 | 1133 | 0.200 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 10 | 0.200 |
Why?
|
| Elasticity | 1 | 2021 | 40 | 0.190 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2021 | 6 | 0.190 |
Why?
|
| Diatrizoate | 8 | 1993 | 8 | 0.190 |
Why?
|
| Diatrizoate Meglumine | 8 | 1993 | 8 | 0.190 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2000 | 17 | 0.190 |
Why?
|
| Coronary Artery Bypass | 5 | 1995 | 31 | 0.180 |
Why?
|
| Phytotherapy | 2 | 2011 | 14 | 0.180 |
Why?
|
| Aortic Aneurysm | 1 | 2000 | 16 | 0.180 |
Why?
|
| Disease Progression | 4 | 2010 | 830 | 0.180 |
Why?
|
| Intraoperative Complications | 2 | 2000 | 75 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2012 | 47 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 1311 | 0.170 |
Why?
|
| Myocardial Ischemia | 3 | 2020 | 49 | 0.170 |
Why?
|
| Hypolipidemic Agents | 1 | 2019 | 23 | 0.160 |
Why?
|
| Sonication | 5 | 2000 | 5 | 0.160 |
Why?
|
| Dyslipidemias | 1 | 2019 | 23 | 0.160 |
Why?
|
| Hypoglycemic Agents | 3 | 2009 | 60 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 89 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2020 | 61 | 0.160 |
Why?
|
| Intra-Abdominal Fat | 2 | 2009 | 44 | 0.160 |
Why?
|
| Peptides | 1 | 2019 | 97 | 0.160 |
Why?
|
| Dogs | 16 | 1996 | 263 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 101 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Thiazolidinediones | 2 | 2008 | 14 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 274 | 0.150 |
Why?
|
| Nitroglycerin | 1 | 1997 | 4 | 0.140 |
Why?
|
| Iopamidol | 1 | 1997 | 3 | 0.140 |
Why?
|
| Blood Pressure | 3 | 1997 | 261 | 0.140 |
Why?
|
| Intraoperative Care | 3 | 1995 | 46 | 0.140 |
Why?
|
| Myocardial Contraction | 2 | 1987 | 72 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 35 | 0.140 |
Why?
|
| Thrombolytic Therapy | 2 | 2012 | 58 | 0.140 |
Why?
|
| Systole | 1 | 1996 | 19 | 0.140 |
Why?
|
| Prognosis | 5 | 2017 | 919 | 0.140 |
Why?
|
| Glucose | 5 | 2019 | 65 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 360 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 468 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 128 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 5189 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 35 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2016 | 21 | 0.130 |
Why?
|
| Software | 2 | 2022 | 72 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2017 | 164 | 0.130 |
Why?
|
| Ventricular Function, Right | 1 | 1995 | 6 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 44 | 0.130 |
Why?
|
| Femoral Artery | 1 | 2015 | 14 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2011 | 499 | 0.120 |
Why?
|
| United States | 6 | 2021 | 2375 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2019 | 1897 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 216 | 0.120 |
Why?
|
| Particulate Matter | 1 | 2014 | 24 | 0.120 |
Why?
|
| Blood Flow Velocity | 3 | 2004 | 20 | 0.120 |
Why?
|
| Transducers | 2 | 2008 | 11 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1009 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 324 | 0.110 |
Why?
|
| Liver | 1 | 2015 | 184 | 0.110 |
Why?
|
| Administration, Intravesical | 1 | 2013 | 6 | 0.110 |
Why?
|
| Algorithms | 2 | 2015 | 414 | 0.110 |
Why?
|
| History, 20th Century | 3 | 2004 | 70 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 42 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2011 | 452 | 0.110 |
Why?
|
| Menopause | 1 | 2014 | 131 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 10 | 0.110 |
Why?
|
| Renal Agents | 1 | 2012 | 3 | 0.110 |
Why?
|
| Pulmonary Artery | 2 | 1992 | 46 | 0.110 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1992 | 7 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2012 | 44 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1992 | 44 | 0.100 |
Why?
|
| Microvessels | 1 | 2011 | 17 | 0.100 |
Why?
|
| Rats | 1 | 2014 | 873 | 0.100 |
Why?
|
| Electrocardiography | 1 | 1992 | 198 | 0.100 |
Why?
|
| Comorbidity | 3 | 2013 | 508 | 0.100 |
Why?
|
| Contrast Sensitivity | 1 | 2011 | 6 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 330 | 0.090 |
Why?
|
| Triglycerides | 1 | 2011 | 47 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2010 | 5 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 2 | 2008 | 4 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 147 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 55 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 260 | 0.090 |
Why?
|
| Myocardium | 6 | 1998 | 146 | 0.090 |
Why?
|
| Swine | 1 | 2010 | 92 | 0.090 |
Why?
|
| Lythraceae | 1 | 2009 | 2 | 0.090 |
Why?
|
| Beverages | 1 | 2009 | 10 | 0.080 |
Why?
|
| Cardioplegic Solutions | 3 | 1995 | 3 | 0.080 |
Why?
|
| Arteritis | 1 | 1989 | 3 | 0.080 |
Why?
|
| Phenylpropanolamine | 1 | 1989 | 2 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 36 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 21 | 0.080 |
Why?
|
| Abdomen | 1 | 2009 | 11 | 0.080 |
Why?
|
| Acoustics | 1 | 2008 | 17 | 0.080 |
Why?
|
| Decompression Sickness | 2 | 2007 | 3 | 0.080 |
Why?
|
| Inpatients | 1 | 2010 | 150 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2008 | 11 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2009 | 78 | 0.080 |
Why?
|
| Subcutaneous Fat | 1 | 2008 | 10 | 0.080 |
Why?
|
| Heart | 5 | 1998 | 96 | 0.080 |
Why?
|
| Drug Combinations | 7 | 1993 | 68 | 0.080 |
Why?
|
| Hemosiderin | 1 | 2007 | 1 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 1 | 0.080 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 4 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2007 | 14 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 1989 | 140 | 0.070 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2007 | 20 | 0.070 |
Why?
|
| Young Adult | 1 | 2013 | 2063 | 0.070 |
Why?
|
| Angiography | 2 | 2022 | 42 | 0.070 |
Why?
|
| Aging | 2 | 2015 | 1727 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 1987 | 38 | 0.070 |
Why?
|
| Particle Size | 4 | 1992 | 71 | 0.070 |
Why?
|
| Research Design | 1 | 2007 | 219 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 1998 | 54 | 0.060 |
Why?
|
| Splanchnic Circulation | 1 | 1984 | 3 | 0.060 |
Why?
|
| Calcium | 2 | 2007 | 503 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 105 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2017 | 2043 | 0.060 |
Why?
|
| Chicago | 2 | 2009 | 943 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2004 | 120 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 500 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 430 | 0.050 |
Why?
|
| Paraffin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Regional Blood Flow | 3 | 1995 | 15 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 662 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2022 | 16 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2022 | 35 | 0.050 |
Why?
|
| Dialysis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Renal Circulation | 2 | 1993 | 6 | 0.050 |
Why?
|
| Urination | 1 | 2021 | 5 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 70 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 43 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 71 | 0.050 |
Why?
|
| Logistic Models | 2 | 2013 | 409 | 0.050 |
Why?
|
| Microcirculation | 4 | 1998 | 42 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 407 | 0.040 |
Why?
|
| Serum Albumin | 2 | 1992 | 25 | 0.040 |
Why?
|
| Injections | 2 | 1992 | 59 | 0.040 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 3 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 161 | 0.040 |
Why?
|
| Perfusion | 3 | 1993 | 22 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 442 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 4 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2019 | 5 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 3 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2002 | 185 | 0.040 |
Why?
|
| Adenoviridae | 1 | 1999 | 19 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 55 | 0.040 |
Why?
|
| Homeostasis | 1 | 2019 | 86 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2019 | 65 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 134 | 0.040 |
Why?
|
| Reference Values | 2 | 2009 | 229 | 0.040 |
Why?
|
| Plasminogen Activators | 1 | 1998 | 2 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3806 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 43 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1998 | 49 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 341 | 0.040 |
Why?
|
| Endocardium | 1 | 1997 | 5 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 2 | 1998 | 8 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 1997 | 20 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1997 | 3 | 0.040 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1997 | 6 | 0.040 |
Why?
|
| Blood | 2 | 1995 | 25 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 1997 | 17 | 0.030 |
Why?
|
| Models, Biological | 2 | 2016 | 346 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 498 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 1996 | 20 | 0.030 |
Why?
|
| Utilization Review | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pressure | 1 | 1996 | 63 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 135 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 21 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1995 | 51 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1995 | 16 | 0.030 |
Why?
|
| Models, Structural | 2 | 1993 | 5 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 107 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 130 | 0.030 |
Why?
|
| Muscles | 1 | 1995 | 72 | 0.030 |
Why?
|
| Monitoring, Physiologic | 2 | 1992 | 93 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 243 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 177 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 329 | 0.030 |
Why?
|
| Role | 1 | 2013 | 8 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 96 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2013 | 90 | 0.030 |
Why?
|
| Heart Arrest | 1 | 1994 | 53 | 0.030 |
Why?
|
| Kidney | 1 | 1995 | 181 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 126 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 1997 | 207 | 0.030 |
Why?
|
| Rheology | 1 | 1993 | 3 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 320 | 0.030 |
Why?
|
| Reference Standards | 1 | 1992 | 32 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1992 | 26 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1992 | 41 | 0.030 |
Why?
|
| Esophagus | 2 | 1991 | 74 | 0.030 |
Why?
|
| Mass Screening | 1 | 2013 | 186 | 0.030 |
Why?
|
| Oxygen | 1 | 1992 | 87 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 370 | 0.020 |
Why?
|
| Aorta | 2 | 1991 | 28 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 873 | 0.020 |
Why?
|
| Selectins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 23 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 121 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 75 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 36 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 98 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Polyphenols | 1 | 2009 | 5 | 0.020 |
Why?
|
| Phenols | 1 | 2009 | 8 | 0.020 |
Why?
|
| Flavonoids | 1 | 2009 | 21 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1922 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 81 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 72 | 0.020 |
Why?
|
| Embolism | 1 | 1989 | 3 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 63 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 148 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 291 | 0.020 |
Why?
|
| Air | 1 | 1989 | 6 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2009 | 15 | 0.020 |
Why?
|
| Lasers | 1 | 1989 | 21 | 0.020 |
Why?
|
| Antioxidants | 1 | 2009 | 65 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1989 | 86 | 0.020 |
Why?
|
| Critical Illness | 1 | 2010 | 141 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2008 | 2 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 5 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1989 | 64 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 116 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 300 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1989 | 80 | 0.020 |
Why?
|
| Empirical Research | 1 | 2007 | 3 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 144 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1994 | 991 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 273 | 0.020 |
Why?
|
| Sorbitol | 2 | 1984 | 4 | 0.020 |
Why?
|
| Cardiac Catheterization | 2 | 1989 | 96 | 0.020 |
Why?
|
| Embolism, Paradoxical | 1 | 2007 | 8 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 83 | 0.020 |
Why?
|
| Radiography | 1 | 1989 | 695 | 0.020 |
Why?
|
| Autoanalysis | 1 | 1986 | 3 | 0.020 |
Why?
|
| Automation | 1 | 1986 | 11 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 1986 | 19 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 511 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 379 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1987 | 225 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 1984 | 27 | 0.010 |
Why?
|
| Cats | 1 | 1984 | 75 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 215 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1984 | 49 | 0.010 |
Why?
|
| Stroke | 1 | 2007 | 315 | 0.010 |
Why?
|
| Intraoperative Period | 2 | 1994 | 33 | 0.010 |
Why?
|
| Densitometry | 2 | 1995 | 11 | 0.010 |
Why?
|
| Medical Laboratory Science | 1 | 2000 | 9 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 23 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 11 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 36 | 0.010 |
Why?
|
| Luciferases | 1 | 1999 | 24 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1999 | 75 | 0.010 |
Why?
|
| Indicator Dilution Techniques | 2 | 1989 | 2 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1999 | 63 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1999 | 118 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1999 | 78 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 37 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1998 | 50 | 0.010 |
Why?
|
| Cineradiography | 1 | 1998 | 1 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 148 | 0.010 |
Why?
|
| Patient Admission | 1 | 1998 | 30 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1998 | 33 | 0.010 |
Why?
|
| Medicare | 1 | 1998 | 127 | 0.010 |
Why?
|
| Adenosine | 1 | 1995 | 11 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1995 | 33 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1995 | 39 | 0.010 |
Why?
|
| Papaverine | 1 | 1995 | 4 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1995 | 9 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 336 | 0.010 |
Why?
|
| Verapamil | 1 | 1995 | 35 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1995 | 28 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1995 | 74 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 1994 | 14 | 0.010 |
Why?
|
| Mice | 1 | 1999 | 1683 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1993 | 40 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1993 | 11 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 691 | 0.010 |
Why?
|
| Constriction | 1 | 1991 | 4 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1991 | 9 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 1991 | 39 | 0.010 |
Why?
|
| Electromagnetic Phenomena | 1 | 1989 | 3 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 1989 | 4 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 6 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 1989 | 7 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1988 | 16 | 0.000 |
Why?
|
| Scattering, Radiation | 1 | 1986 | 40 | 0.000 |
Why?
|
| Microcomputers | 1 | 1984 | 5 | 0.000 |
Why?
|
| Half-Life | 1 | 1984 | 15 | 0.000 |
Why?
|
| Computers | 1 | 1984 | 27 | 0.000 |
Why?
|
| Pulmonary Circulation | 1 | 1984 | 5 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1984 | 23 | 0.000 |
Why?
|